Small intestine gastrointestinal stromal tumors
Current Opinion in Gastroenterology, 03/02/2012
Advances in the last decade have dramatically changed the management and prognosis of patients with primary and advanced gastrointestinal stromal tumor (GIST).
Tumor size, mitotic count, and site of origin are the three key prognostic factors, with mitotic count being the single strongest predictor of recurrence.
Tumors arising in the small bowel have worse prognosis than those of comparable size and mitotic count arising in other organs.
Endoscopy and endoscopic ultrasound-guided, fine-needle aspiration are key components in the diagnosis of GIST.
The role of endoscopy in surveillance and resection remain investigational.
Surgery, either open or laparoscopic, remains the only curative option, but recurrence rates are high.
Adjuvant therapy with imatinib mesylate improves recurrence-free survival rates and may improve overall survival (OS) with longer duration of treatment.
Neoadjuvant imatinib may play an important role in the management of patients with locally advanced disease.
For patients with advanced disease, first-line imatinib and second-line sunitinib malate have improved progression-free and OS rates.
Systemic treatment should be continued life-long or until treatment failure.